Balyasny Asset Management
HQL

Balyasny Asset Management’s abrdn Life Sciences Investors HQL Stock Holding History

Balyasny Asset Management’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,340
Closed -$284K – 3291
2025
Q3 		$284K Buy
+18,340
New +$251K ﹤0.01% 2595

Other funds holding HQL

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Balyasny Asset Management's HQL Position: Q4 2025 in Review

Balyasny Asset Management sold out of abrdn Life Sciences Investors (HQL) in Q4 2025, closing a stake of 18,340 shares — an estimated $284K sold.

Balyasny Asset Management first reported a position in HQL in Q3 2025 and held it in 1 quarter. The position peaked at $284K in Q3 2025. 73 funds tracked by Wall St. Rank hold HQL as of Q4 2025.

  • Balyasny Asset Management reported no remaining abrdn Life Sciences Investors position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 18,340 abrdn Life Sciences Investors shares in Q4 2025, an estimated $284K.
  • Balyasny Asset Management first reported a position in abrdn Life Sciences Investors in Q3 2025 and held it in 1 quarter.
  • Balyasny Asset Management's abrdn Life Sciences Investors position peaked at $284K in Q3 2025.
  • 73 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.